BOEHRINGER-INGELHEIM
5.9.2016 16:34:30 CEST | Business Wire | Press release
Boehringer Ingelheim today announced a new post-hoc subanalysis of the WISDOM study that suggests only 4 out of 100 people with chronic obstructive pulmonary disease (COPD), who have a history of frequent exacerbations and raised eosinophil levels (≥400 cells/µL), may further benefit by adding inhaled corticosteroids (ICS, fluticasone propionate 500µg twice daily) to Spiriva® (tiotropium 18μg once daily) and a long-acting beta2-agonist (LABA, salmeterol 50μg twice daily) with regard to reducing exacerbation risk.1,3 Eosinophils, which are a type of white blood cell, are assessed as part of a routine blood test.4 This new post-hoc subanalysis was presented today at the European Respiratory Society (ERS) International Congress 2016 in London.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160905005424/en/
“New results from the WISDOM study indicate that using ICS as part of a triple therapy regimen in COPD maintenance treatment reduces the likelihood of an exacerbation for a smaller number of people than previously thought. It challenges our current understanding of the appropriate use of ICS in COPD maintenance therapy,” said study investigator Professor Peter Calverley, Professor of Pulmonary Medicine, University of Liverpool, UK. “These study results add important information to a debate that has potentially wide-ranging implications for the future treatment of people with COPD.”
Exacerbations significantly contribute to the impact of COPD, often leading to the person being admitted to a hospital,5 and can increase the risk of death.6 The Global Initiative for Chronic Obstructive Lung Disease (GOLD), which is a collaboration between the World Health Organization and the US National Institutes of Health, recommends the use of ICS-containing therapy only in people with COPD who have severe to very severe lung function impairment and/or are at high risk of exacerbations (GOLD C/D) or who have had a hospitalisation7 – the patient population studied in WISDOM. However, ICS are widely used outside of GOLD treatment recommendations in combination with bronchodilators, such as tiotropium and LABAs, in the treatment of COPD.8
This new post-hoc subanalysis suggests that by combining history of frequent exacerbations (two or more exacerbations in the past twelve months) with raised blood eosinophil levels of ≥400 cells/µL, healthcare providers may more precisely identify the minority of people with COPD who could experience a further exacerbation risk reduction from ICS (fluticasone propionate) on top of tiotropium and a LABA (salmeterol).1,3
This finding further builds on an earlier post-hoc analysis of the WISDOM trial, which evaluated blood eosinophil levels alone, and indicated that people with blood eosinophil levels higher than ≥300 cells/µL had an additional exacerbation reduction from ICS (fluticasone propionate) on top of tiotropium and a LABA (salmeterol).2
The 52-week WISDOM study (NCT00975195) evaluated the effect of ICS (fluticasone propionate) withdrawal in people with severe to very severe COPD having a history of exacerbation, while receiving tiotropium and a LABA (salmeterol).9 The patient population of the WISDOM trial represents approximately 20 percent of the normal COPD patient population10 and only 4 percent of this population were known to have a history of frequent exacerbations (two or more exacerbations in the past twelve months) with raised blood eosinophil levels of ≥400 cells/µL.1,3
“Boehringer Ingelheim is committed to continuing scientific research that informs the optimal treatment of people with COPD. These findings add to our understanding of the factors that should be considered by healthcare providers when deciding a treatment regimen for people with COPD – specifically when to add an ICS,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “In addition, these findings highlight the importance of further investigation and discussion of this topic.”
In the WISDOM study population, complete ICS (fluticasone propionate) withdrawal was associated with a small reduction in trough FEV1 .9 The earlier post-hoc analysis showed overall no relationship between blood eosinophil count and change in lung function with ICS (fluticasone propionate) withdrawal.2 However, the latest post-hoc subanalysis indicated a relevant reduction in trough FEV1 in the small subgroup of people with high eosinophil count and frequent exacerbations.11
COPD is a serious but manageable lung disease, which is estimated to affect 210 million people worldwide.12 Total deaths from COPD are projected to increase by more than 30 percent in the next 10 years; COPD is predicted to become the third leading cause of death globally by 2030.13
For ‘Notes to Editors’ and ‘References’ please visit: https://www.boehringer-ingelheim.com/press-release/simple-blood-test-help-to-identify-when-to-add-ics
View source version on businesswire.com: http://www.businesswire.com/news/home/20160905005424/en/
Contact:
Boehringer Ingelheim
Corporate Communications
Media
+ PR
Carolin Grob
Email: carolin.grob@boehringer-ingelheim.com
Phone:
+49 (6132) 77-182603
Fax: +49 (6132) 77-6601
Email: press@boehringer-ingelheim.com
www.boehringer-ingelheim.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
